Abivax Shares Jump After Phase 3 Obefazimod Data Shows Strong Remission Rates in Ulcerative Colitis
Abivax shares climbed 20% after the company reported that its Phase 3 ABTECT maintenance trial for obefazimod met the primary endpoint. Both 25 mg and 50 mg once-daily doses produced markedly higher clinical remission rates at Week 44 versus placebo, and the trial met all key secondary endpoints with no new safety signals reported over the 44-week …